PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperv

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known 09/517,898 Application Number March 3, 2000 Filing Date Vogels et al. First Named Inventor 1632 Group Art Unit Q. Li Examiner Name

2578-3982.2US of Attorney Docket Number

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
Xa		US-5,631,236	05-1997	Woo et al.	
A		US- 5,770,442	06-1998	Wickham et al.	
	T	US-			
		US-			(:
		US-			
		US-			
	Ì	US-			
	1	US-			
		US-			
		US-			
	1	US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	_T ⁶
	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
0		97/00326	01/03/1997	Introgene B.V.		
	, ,		1			
	1		1 1			

Examiner Signature	& flirt.	Date Considered	6/20/02	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Account 199

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known

Application Number 09/517,898

Filing Date March 3, 2000

First Named Inventor Vogels et al.

Group Art Unit 1632

Examiner Name Q. Li

Attorney Docket Number 2578-3982 2US

(use as many sheets as necessary)

Examiner

Signature

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т :
		Crystal et al., Transfer of Gene to Human: Early Lessons and Obstacles to Success, 1995, Science, Vol. 270, pp. 404-10.	
		Eck et al., Gene-Based Therapy, 1996 Goodman & Gilman's, pp. 77-101.	
		Gall et al., Journal of Virology, 1996, pp. 2116-23, Vol. 70.	
		Guzman et al., PNAS, 1994, pp. 10732-36, Vol. 91.	
		Kaye et al., A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding, September 1990, Proc. Natl. Acad. Sci., pp. 6922-26, Vol. 87.	
		Lusky et al., Journal of Virology, 1998, pp. 2022-32, Vol. 72.	
~ <i>C</i>		Rudinger et al., Characteristics of the armino acids as components of a peptide hormone sequence, 1976, Peptide Hormones, pp. 1-7.	
		Su, et al., A Genetically Modified Adenoviral Vector Exhibits Enhanced Gene Transfer of Human Smooth Muscle Cells, Journal of Vascular Research 2001, pp. 471-78, Vol. 38.	
To		Wickham et al., Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Protein, Nov. 1997, Journal of Virology, pp. 8221-29, Vol. 71, No. 11.	
X		Wilson et al., Adenovirus Vectors in the Development of Gene Therapy, 1999, Friedman, T ed. CSHL Press, Cold Spring Harbor, New York.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.